Pharma Horizons: Artificial Intelligence
By European Pharmaceutical Review
The case for immigration concessions: maintaining the UK’s competitiveness in science and technology
By Ana Sofia Walsh (Fragomen LLP), Rajiv Naik (Fragomen LLP)
Tariffs could threaten medicine innovation, industry bodies warn
By Catherine Eckford (European Pharmaceutical Review)
FDA approves first-in-class oral antibiotic
By Catherine Eckford (European Pharmaceutical Review)
The case for immigration concessions: maintaining the UK’s competitiveness in…
By Ana Sofia Walsh (Fragomen LLP), Rajiv Naik (Fragomen LLP)
Preparing for a new era in the rare disease sector
By Catherine Eckford (European Pharmaceutical Review), Christina Gkousgkouni (Sanofi)